Cytisine (Citidaron®). HTA ID: 23063

Assessment Status Rapid Review Complete
HTA ID 23063
Drug Cytisine
Brand Citidaron®
Indication Cytisine (Citidaron®) is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking.
Assessment Process
Rapid review commissioned 09/10/2023
Rapid review completed 28/11/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that cytisine not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.